Quantcast

Industry news that matters to you.  Learn more

Outcomes Study Supports Use of LDL Particle Number to Guide Statin Therapy in Patients at Elevated Cardiovascular Risk

LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, recently announced data suggesting that the use of a target low-density lipoprotein particle (LDL-P) number to guide statin therapy in at-risk patients can reduce the risk of major adverse cardiovascular events (MACE) and death, compared to using standard LDL cholesterol (LDL-C) targets as a guide to therapy. Such benefits are particularly pronounced in patients in whom LDL-P and LDL-C numbers disagree, as is common in people with diabetes mellitus or coronary heart disease (CHD).

Cardiac Biomarker ST2 Proves Far Superior To Galectin-3 In A Head-to-Head Study

Critical Diagnostics recently announced that the study, “Head-to-head comparison of two myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 vs. Galectin-3”, recently published online in JACC (the Journal of the American College of Cardiology) comparing the company’s novel cardiac biomarker ST2 to Galectin-3 (Gal-3), a biomarker from BG Medicine (NASDAQ: BGMD), found ST2 to be superior.

Sanofi Announces Upcoming Launch of MyStar Extra, the First Self-Monitoring Blood Glucose Meter With Estimated A1c

At the annual meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain, Sanofi (EURONEXT : SAN and NYSE : SNY) recently presented the innovative blood glucose meter MyStar Extra®, the first self-monitoring device that provides robust estimates of the A1c value, a key indicator for long-term glucose control.[3],[4] The hemoglobin A1C (HbA1C) assay has become the cornerstone for the assessment of diabetes control and A1c test results are widely used to guide treatment decisions.[5],[6] Especially convenient for people starting on insulin or using insulin, MyStar Extra® is a supportive meter, designed to help people with diabetes be engaged in their insulin management and treatment plan.[7],[8],[9]

New Test Assesses Gestational Diabetes Risk Early in Pregnancy

Levels of a biomarker in a pregnant woman’s blood can help physicians gauge her risk of developing gestational diabetes during the first trimester, according to a recent study accepted for publication in The Endocrine Society’s Journal of Clinical Endocrinology & Metabolism (JCEM).

Gestational diabetes is a form of diabetes that can develop during pregnancy, often during the second trimester. The condition causes glucose levels in the bloodstream to be higher than normal. Early diagnosis and treatment can help the woman manage the condition. If left untreated, high blood glucose in the mother increases the risk of jaundice, breathing and hypoglycemia problems in the newborn. Uncontrolled gestational diabetes also can increase the risk of premature delivery and preeclampsia, or pregnancy-induced high blood pressure.

“Although it is important to quickly intervene in cases of gestational diabetes, often only women who have risk factors like a family history or obesity are screened early in pregnancy,” said one of the study’s authors, Atsuhiro Ichihara, MD, PhD, of Tokyo Women’s Medical University. “Women who don’t have the traditional risk factors may not be diagnosed until the second trimester. The method identified in this study offers every pregnant woman the opportunity to know her risk early on.”

The prospective cohort study tested the blood of 716 pregnant women during the first trimester to measure their levels of the soluble (pro)renin receptor, or s(P)RR. Of the participants, 44 women developed gestational diabetes.

Researchers found pregnant women with elevated s(P)RR levels were more likely to be diagnosed with gestational diabetes. Women who had the highest s(P)RR levels were 2.9 times more likely to develop gestational diabetes than women who had the lowest levels.

“In addition to gestational diabetes, recent studies have found elevated s(P)RR levels are associated with the birth of larger babies and high blood pressure in late pregnancy,” Ichihara said. “The evidence suggests the biomarker is important in the interaction between mother and fetus during pregnancy.”

Source: Prediction of Gestational Diabetes Mellitus by Soluble (Pro)Renin Receptor during the First Trimester

Source: EurekAlert!

Myriad Announces Diabetes Collaboration With Sanofi

Myriad Genetics (Nasdaq:MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has entered into a research collaboration with Sanofi, a global and diversified healthcare leader, and Population Health Research Institute (PHRI) at Hamilton Health Sciences and McMaster University. Through this collaboration, Myriad RBM will perform protein biomarker research for the Outcome Reduction with Initial Glargine Intervention (ORIGIN) study, the world’s longest and largest randomized clinical trial in pre- and early diabetes. The relationship between the biomarker results and clinical outcomes will be analyzed by investigators at PHRI.